Table 1.
Summary of clinical features of patients
| Pathology | Number of patients | Sex (male: female) | Age (Mean ± SD, y.o.) | Primary tumor pathology (no. of patients) | Primary radiation therapy (no. of patients) | RT dose (Mean ±SD, Gy) | Primary chemotherapy (no. of patients) | Time between RT and this study (Mean ± SD, months) |
|---|---|---|---|---|---|---|---|---|
| RN | 16 | 7 : 9 | 49.1 ± 15.7 | AA: 9 | Ex-RT: 8 | 56.1 ± 9.3 | TMZ: 8 | 28.2 ± 34.4 |
| AO: 2 | SRT: 5 | ACNU + VCR: 2 | ||||||
| GBM: 5 | Proton therapy + RT: 3 | PCV: 1 | ||||||
| CBDCA+VP-16:1 | ||||||||
| None: 4 | ||||||||
| Gr.3 | ||||||||
| 17 | 12 : 5 | 45.7 ± 18.0 | 53.2 ± 4.4 | 39.8 ± 41.8 | ||||
| AA | 7 | 6 : 1 | 45.9 ± 19.2 | AA: 7 | Ex-RT: 5 | 54.6 ± 4.6 | TMZ: 1 | 34.0 ± 49.0 |
| SRT: 2 | MCNU: 1 | |||||||
| CBDCA+VP-16: 1 | ||||||||
| None: 4 | ||||||||
| AO | 10 | 6 : 4 | 45.6 ± 18.1 | AO: 10 | Ex-RT: 10 | 52.2 ± 4.2 | PCV: 3 | 43.9 ± 38.2 |
| MCNU+INF-β: 1 | ||||||||
| TMZ: 1 | ||||||||
| None: 5 | ||||||||
| Gr.4 | 17 | 7 : 10 | 42.1 ± 15.6 | AA: 7 | Ex-RT: 14 | 60.1 ± 10.2 | TMZ: 5 | 31.6 ± 42.0 |
| GBM: 10 | SRT: 2 | ACNU+VCR: 4 | ||||||
| Proton therapy + RT: 1 | CBDCA+VP-16: 2 | |||||||
| None: 6 |
AA: anaplastic astrocytoma, ACNU: nimustine, AO: anaplastic oligodendroglioma, CBDCA: carboplatin, Ex-RT: conventional external radiation therapy, GBM: glioblastoma, Gr.3: recurrent grade 3- glioma, Gr.4: recurrent glioblastoma, INF-β: interferon-β, MCNU: ranimustine, PCV: procarbazine-lomustine-vincristine sulfate therapy, RN: radiation necrosis, RT: radiation therapy, SD: standard deviation, SRT: stereotactic radiotherapy, TMZ: temozoromide, VCR: vincristine sulfate, VP-16: etoposide, y.o.: years old.